AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04434300
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compare the pharmacokinetic of subcutaneous (SC) and intravenous (IV) routes in the same patient.
Trial: NCT03838484
Drug: Nicotine Patch, 7 Mg/24 Hr
RxNorm normalized name: Nicotine Patch, 7 mg/24 hr transdermal film, extended release
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine patch, 7 mg/24 hour will be applied to the skin.
Trial: NCT02287818
Drug: AC-201
RxNorm normalized name: Japan Yellow 201
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
Trial: NCT02287818
Drug: Febuxostat
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL
Trial: NCT01844856
Drug: Eravacycline
RxNorm normalized name: Eravacycline
DrugBank: Eravacycline (DB12329)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01844856
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02598856
Drug: Intranasal (IN) naloxone 1x
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
Trial: NCT02598856
Drug: Intranasal (IN) naloxone 2
RxNorm normalized name: naloxone 2 MG
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
Trial: NCT03005808
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery for appendicitis
Trial: NCT01649024
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02531165
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
Trial: NCT00718770
Drug: Bexarotene
RxNorm normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
Trial: NCT03596450
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be prescribed commercially available semaglutide s.c. and will be instructed to initiate treatment with semaglutide s.c. according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
Trial: NCT02162966
Drug: High Dose Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High Dose Colistin
Trial: NCT02162966
Drug: Standard Dose Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Dose Colistin
Trial: NCT02531165
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
Trial: NCT02531165
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg loading dose orally (or intravenously), followed by 100 mg od
Trial: NCT00381030
Drug: carvedilol plus nurse management
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00801021
Drug: Frio Mouth Rinse
RxNorm normalized name: moth bean extract
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinse with 15ml twice daily then expectorate
Trial: NCT02576808
Drug: Ginger extract
RxNorm normalized name: ginger extract
DrugBank: Ginger (DB10344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
Trial: NCT02576808
Drug: Loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
Trial: NCT03766763
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day.~* For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ).~* For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment).
Trial: NCT02138357
Drug: buprenorphine transdermal delivery system (BTDS)
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00006056
Drug: anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006056
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006056
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00841438
Drug: Clotinab
RxNorm normalized name: Olorinab
DrugBank: Olorinab (DB14998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
Trial: NCT00006056
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00006056
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00998634
Drug: LITHIUM CARBONATE
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
Trial: NCT00286416
Drug: omalizumab (Xolair)
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01703793
Drug: Vehicle (placebo)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03639506
Drug: intracytoplasmic sperm injection (ICSI)
RxNorm normalized name: herring sperm DNA
DrugBank: Herring (DB10617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intracytoplasmic sperm injection (ICSI)
Trial: NCT02654665
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GLP-1 agonist
Trial: NCT01227512
Drug: tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
Trial: NCT01445392
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg/m\^2 on day 1 of each 21 day cycle until disease progression
Trial: NCT01445392
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 on day 1 of each 21 day cycle until disease progression
Trial: NCT04055116
Drug: Buffered Lidocaine
RxNorm normalized name: buffered lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
Trial: NCT01357759
Drug: MORAb-022
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
Trial: NCT01124981
Drug: Human albumin (Placebo)
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
Trial: NCT01579630
Drug: Pemetrexed 500mg/m2 iv
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
Trial: NCT01579630
Drug: Pemetrexed 500mg/m2 iv and Gefitinib 250 mg
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
Trial: NCT00885300
Drug: cloxacillin
RxNorm normalized name: Cloxacillin
DrugBank: Cloxacillin (DB01147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
Trial: NCT04596150
Drug: CX-2009
RxNorm normalized name: CX-2009
DrugBank: CX-2009 (DB16090)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W)
Trial: NCT00290667
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00290667
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04596150
Drug: CX-072
RxNorm normalized name: Cx-072 probody
DrugBank: Pacmilimab (DB18873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)
Trial: NCT00901875
Drug: Buprenorphine + naloxone (Suboxone)
RxNorm normalized name: buprenorphine / naloxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sublingual tablets
Trial: NCT00901875
Drug: Buprenorphine + naloxone (Suboxone)
RxNorm normalized name: buprenorphine / naloxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02908529
Drug: Combination product of Atomoxetine and Oxybutynin
RxNorm normalized name: atomoxetine Oral Product
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
Trial: NCT02774681
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03053869
Drug: Benzodiazepine - limited use strategy
RxNorm normalized name: 1,2-Benzodiazepine
DrugBank: 1,2-Benzodiazepine (DB12537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. No routine use of any intraoperative benzodiazepines.~2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia.
Trial: NCT03053869
Drug: Benzodiazepine - Ad libitum strategy
RxNorm normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Administration of some benzodiazepine to most patients undergoing cardiac surgery.~2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy).
Trial: NCT02598856
Drug: Intravenous (IV) naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
Trial: NCT02598856
Drug: Intramuscular (IM) naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
Trial: NCT00519688
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg, BID
Trial: NCT00519688
Drug: Tegafur/Uracil
RxNorm normalized name: Tegafur/uracil
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/m2, based on tegafur, BID
Trial: NCT01808820
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
Trial: NCT00960479
Drug: Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
RxNorm normalized name: ribavirin 200 MG
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00960479
Drug: Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
RxNorm normalized name: S-adenosylmethionine 200 MG
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01024387
Drug: AMG 479
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01321957
Drug: Oxaliplatin, 5FU/LV, Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Trial: NCT01321957
Drug: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Trial: NCT03030287
Drug: OMP-305B83
RxNorm normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (in the vein) infusion
Trial: NCT01813565
Drug: Hyaluronic acid/chondroitin sulfate
RxNorm normalized name: hyaluronic acid/chondroitin sulfate/collagen II/amino acids 40 mg-80 mg-400 mg ORAL CAPSULE
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
Trial: NCT03030287
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: administered intravenously
Trial: NCT03330184
Drug: Berberine Hydrochloride group
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03330184
Drug: Bifidobacterium group
RxNorm normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03330184
Drug: Berberine Hydrochloride and Bifidobacterium group
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00015951
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00015951
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05731934
Drug: HX301
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
Trial: NCT02623504
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
Trial: NCT00279565
Drug: buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00279565
Drug: methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00279565
Drug: pegylated interferon alfa-2b plus ribavirin
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04331600
Drug: Chloroquine phosphate
RxNorm normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chloroquine phosphate for 14 days
Trial: NCT00619021
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 dose levels designated by cohort; 600 mg/m\^2, 800 mg/m\^2, 1000 mg/m\^2, 1200 mg/m\^2
Trial: NCT01263145
Drug: Akt Inhibitor MK2206
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01263145
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00804947
Drug: Intravenous busulfan and melphalan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
Trial: NCT01394926
Drug: Optison
RxNorm normalized name: Optison
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
Trial: NCT04081272
Drug: Sodium Chromate Cr51
RxNorm normalized name: sodium chromate Cr51
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
Trial: NCT00226135
Drug: lithium or lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01737294
Drug: Qutenza exposure
RxNorm normalized name: Qutenza
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cutaneous patch
Trial: NCT01989611
Drug: emtricitabine / tenofovir 200/300 mg
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
Trial: NCT00389155
Drug: Vinflunine
RxNorm normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
Trial: NCT00927394
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg tablet
Trial: NCT00389155
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
Trial: NCT00927394
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 160 mg capsules
Trial: NCT00927394
Drug: Placebo for Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for Aliskiren 150 mg tablets
Trial: NCT00606983
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration of Tamsulosin
Trial: NCT01189643
Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.